Anzahl der Publikationen: 7
Zeitschriftenartikel
Fraccaroli, A.; Prevalsek, D.; Häbe, S.; Schulz, C.; Roiss, M.; Bücklein, V.; Lippl, S.; Herold, T.; Stemmler, H.-J.; Spiekermann, K.; Ledderose, G.; Hiddemann, W. und Tischer, J.
(2017):
HLA haploidentical allografting using post transplantation cyclophosphamide in high-risk and advanced MDS and AML patients aged over 50 years: feasibility and outcome.
In: Oncology Research and Treatment, Bd. 40: S. 102
Tischer, Johanna; Zoellner, A. K.; Prevalsek, D.; Köhnke, T.; Fritsch, S.; Schulz, C.; Lippl, S.; Kruger, S.; Haebe, S.; Berking, S.; Fraccaroli, A.; Ledderose, G.; Spiekermann, K.; Bug, G.; Hausmann, A.; Schmid, C.; Albert, M. und Hiddemann, W.
(2017):
Haploidentical Stem Cell Transplantation in ALL.
In: Annals of Hematology, Bd. 96:
S39-S40
Haebe, S.; Totok, G.; Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zöllner, A.-K.; Köhnke, T.; Schulz, C.; Ledderose, G.; Hausmann, A.; Hiddemann, W. und Tischer, J.
(2016):
HLA-haploidentical transplantation using T-cell-replete grafts and high-dose cyclophosphamide post-transplantation in the treatment of multiple myeloma: a single center experience.
In: Bone Marrow Transplantation, Bd. 51:
S356-S357
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Koehnke, T.; Buecklein, V. L.; Mumm, F.; Haebe, S.; Witkowski, L.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Sequential therapy in the setting of HLA-haploidentical transplantation utilizing T-cell-replete grafts and post-transplantation high-dose cyclophosphamide in the treatment of relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome.
In: Bone Marrow Transplantation, Bd. 51:
S29-S30
Prevalsek, D.; Fritsch, S.; Hubmann, M.; Zoellner, A.-K.; Köhnke, T.; Engel, N.; Bücklein, V. L.; Schulz, C.; Mumm, F.; Berking, S.; Ledderose, G.; Stemmler, H.-J.; Spiekermann, K.; Hiddemann, W.; Hausmann, A. und Tischer, J.
(2016):
Results of sequential therapy in the setting of unmanipulated HLA-haploidentical transplantation utilizing post-transplantation high-dose cyclophosphamide in the treatment of high-risk AML and MDS.
In: Oncology Research and Treatment, Bd. 39: S. 77-78
Schmid, C.; Schleuning, M.; Hentrich, M.; Markl, G. E.; Gerbitz, A.; Tischer, J.; Ledderose, G.; Oruzio, D.; Hiddemann, Wolfgang und Kolb, H. J.
(2008):
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
In: Bone Marrow Transplantation, Bd. 41, Nr. 8: S. 721-727
Schmid, C.; Schleuning, M.; Aschan, J.; Ringden, O.; Hahn, J.; Holler, E.; Hegenbart, U.; Niederwieser, D. W.; Dugas, Martin; Ledderose, G. und Kolb, H. J.
(2004):
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation [2].
In: Leukemia, Bd. 18, Nr. 8: S. 1430-1433
Diese Liste wurde am
Sat Nov 23 23:48:30 2024 CET
erstellt.